Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor
(GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl …

Importance Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …

Diabetic kidney disease develops in approximately 40% of patients who are diabetic and is
the leading cause of CKD worldwide. Although ESRD may be the most recognizable …

Summary Background In the Canagliflozin Cardiovascular Assessment Study (CANVAS)
Program, canagliflozin reduced the rates of major adverse cardiovascular events and the …

Diabetic kidney disease (DKD) is a major cause of morbidity and mortality in patients with
diabetes mellitus and the leading cause of end-stage renal disease in the world. The most …

There is currently an unmet need for effective treatment of chronic kidney disease (CKD) that
slows disease progression, prevents development of end-stage kidney disease and …

Background In a pooled analysis of short-term trials, short-term treatment with the sodium-
glucose co-transporter-2 (SGLT2) inhibitor empagliflozin reduced albuminuria in patients …

As the prevalence of diabetes continues to climb, the number of individuals living with
diabetic complications will reach an unprecedented magnitude. The emergence of new …

The gastrointestinal tract—the largest endocrine network in human physiology—
orchestrates signals from the external environment to maintain neural and hormonal control …